Last reviewed · How we verify
Incidence of acute kidney injury — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Incidence of acute kidney injury (Incidence of acute kidney injury) — Hospices Civils de Lyon.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Incidence of acute kidney injury TARGET | Incidence of acute kidney injury | Hospices Civils de Lyon | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Incidence of acute kidney injury CI watch — RSS
- Incidence of acute kidney injury CI watch — Atom
- Incidence of acute kidney injury CI watch — JSON
- Incidence of acute kidney injury alone — RSS
Cite this brief
Drug Landscape (2026). Incidence of acute kidney injury — Competitive Intelligence Brief. https://druglandscape.com/ci/incidence-of-acute-kidney-injury. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab